NantHealth & NantOmics Announce Publication of Study Highlighting High Error Rates in Tumor-Only Sequencing for Cancer Treatm...
May 07 2018 - 7:00AM
Business Wire
Research shows approach that includes
sequencing both normal genomes and tumor genomes increases accuracy
and precision
NantHealth, Inc., (NASDAQ: NH), a leading next-generation,
evidence-based, personalized healthcare company, and NantOmics,
LLC, the leader in molecular diagnostics and a member of the
NantWorks ecosystem of families, announced today joint results that
show significant improvements in the accuracy of diagnosis when
combining tumor-normal DNA analysis with tumor RNA analysis
— as well as the risk for a higher error rate in tumor-only
sequencing.
The research is included in a paper, “Comprehensive genomic
transcriptomic tumor-normal gene panel analysis for enhanced
precision in patients with lung cancer,” published last month in
the online journal Oncotarget.
Dr. Patrick Soon-Shiong, CEO and founder of NantHealth and
NantOmics, said the publication showed the significance of
combining tumor and normal DNA sequencing in diagnosis — and
highlighted the precision of NantOmics’ GPS Cancer test.
“Our research shows the potential peril in using tumor-only
sequencing for lung cancer patients,” Soon-Shiong said. “The
Centers for Medicare and Medicaid Services is only reimbursing for
sequencing and analysis of a 35 gene panel for lung cancer, with
the patient’s normal DNA explicitly excluded. Our research shows
there’s a serious risk of erroneous analysis in a tumor-only
approach.”
Oncotarget is a multidisciplinary traditional journal focused on
making scientific results rapidly and widely available so that
exceptional discoveries can be shared quickly.
The published results of the NantOmics and NantHealth study show
the precision derived from GPS Cancer’s comprehensive approach that
combines tumor and normal DNA sequencing with RNA sequencing.
Highlights from the study include:
- 95 percent of genomic variants
identified from tumor-only sequencing originated in the germline,
therefore, these variants were single nucleotide polymorphisms
(SNPs) and false positive tumor somatic variants.
- After filtering based on population
allele frequency to remove SNPs, the false positive rate remained
as high as 48 percent.
- 29 percent of lung cancer patients had
a false positive variant call in at least one of 12 genes with
directly targetable drugs.
- 18 percent of true somatic variants
identified from tumor and normal DNA sequencing were not expressed
in RNA, showing the importance of RNA sequencing to verify gene and
variant expression.
In a clinical setting, it is important to sequence the tumor and
normal DNA as well as the tumor RNA as treatment decisions based on
tumor-only sequencing may result in ineffective therapies while
also increasing the risk of negative drug-related side effects. GPS
Cancer provides a precise and comprehensive molecular profile,
integrating tumor-normal sequencing of DNA with RNA sequencing.
This approach overcomes the challenges faced by tumor-only DNA
sequencing, equipping oncologists with insights that they can rely
on to inform their personalized treatment strategies.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of
companies, is a next-generation, evidence-based, personalized
healthcare company enabling improved patient outcomes and more
effective treatment decisions for critical illnesses. NantHealth's
unique systems-based approach to personalized healthcare applies
novel diagnostics tailored to the specific molecular profiles of
patient tissue and integrates this molecular data in a clinical
setting with large-scale, real-time biometric signal and phenotypic
data to track patient outcomes and deliver precision medicine. For
nearly a decade, NantHealth has developed an adaptive learning
system that integrates our unique molecular profiling solution,
software and hardware. Our system infrastructure collects, indexes,
analyzes and interprets billions of molecular, clinical,
operational and financial data points derived from novel and
traditional sources to continuously improve decision-making and
optimize our clinical pathways and decision algorithms over time.
For more information please visit www.nanthealth.com.
About NantOmics, LLC
NantOmics, a member of the NantWorks ecosystem of companies,
delivers molecular diagnostic capabilities with the intent of
providing actionable intelligence and molecularly driven decision
support for cancer patients and their providers at the point of
care. NantOmics is the first molecular diagnostics company to
pioneer an integrated approach to unearthing the genomic and
proteomic variances that initiate and drive cancer, by analyzing
both normal and tumor cells from the same patient and following
identified variances through from DNA to RNA to protein to drug.
NantOmics has a highly scalable cloud-based infrastructure capable
of storing and processing thousands of genomes a day, computing
genomic variances in near real-time, and correlating proteomic
pathway analysis with quantitative multi-plexed protein expression
analysis from the same micro-dissected tumor sample used for
genomic analysis. For more information please
visit www.nantomics.com and follow Dr. Soon-Shiong on
Twitter @DrPatSoonShiong.
About GPS Cancer®
GPS Cancer® is a unique, comprehensive test available
through NantHealth. GPS Cancer integrates tumor/normal DNA and RNA
sequencing, with enhanced expression analysis and bioinformatics of
complex biologic pathway systems, providing oncologists with a
comprehensive molecular profile of a patient’s cancer to inform
personalized treatment strategies. GPS Cancer testing is conducted
in CLIA-certified and CAP-accredited laboratories. For more
information, visit www.gpscancer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180507005485/en/
NANTJen Hodsonjen@nantworks.com
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jun 2024 to Jul 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jul 2023 to Jul 2024